This post was originally published on this site
https://i-invdn-com.akamaized.net/news/LYNXNPEC0K08U_M.jpg
However, the stock has retreated 33% over the past three months. This price retreat can be attributed to the company’s mixed financial performance in the first quarter. BIOL is currently trading 52.6% below its $1.51, 52-week high, indicating short-term bearishness. Although the company has been investing heavily to develop more advanced dental lasers for endodontists, its bleak fundamentals make its growth prospects uncertain.
Click here to checkout our Healthcare Sector Report for 2021
